Hormonal
Pharmacological activation of the BCKD complex using agents like BT2 or Sodium Phenylbutyrate (NaPB) accelerates BCAA catabolism, lowers plasma BCAA levels, and improves insulin sensitivity in animal models of obesity and diabetes.
Current research shows that drugs like BT2 and NaPB can fix BCAA metabolism issues in lab animals, improving insulin sensitivity. However, these are not yet approved or proven safe for humans for this purpose. Focus on exercise and balanced nutrition to naturally support BCAA clearance.
BT2 is a small-molecule inhibitor of BCKDK and accelerates the BCAA catabolic pathway via increased activation of the BCKD complex... administration of BT2 resulted in lower plasma BCAA levels, improved insulin sensitivity and hyperinsulinemia... NaPB... directly enhance BCAA catabolism through stimulation of the BCKD complex... NaPB treatment resulted in lower BCAA concentrations paralleled by improved insulin-stimulated glucose uptake.
Why this rating
Strong evidence in rodent models and in vitro human cells, but limited direct clinical trial data in humans for metabolic improvement.
Source
Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes
Froukje Vanweert et al. · Nutrition and Diabetes · 2022
DOI 10.1038/s41387-022-00213-3
More from this paper
- Endurance and resistance exercise training lowers plasma BCAA levels and enhances BCAA oxidation, serving as a natural strategy to mitigate BCAA-related insulin resistance.Good
- Elevated plasma branched-chain amino acid (BCAA) levels contribute to the development of insulin resistance through multiple mechanisms, including mTOR/S6K-mediated inhibition of insulin signaling, inhibition of pyruvate dehydrogenase (PDH), and accumulation of toxic metabolites causing mitochondrial dysfunction.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →